RxDoctor Payments Data

Sergio Infante, MD

Nephrology · Colton, CANPI 1962611897

Payments from drug & device makers

$9,179in general payments, 2019–2025

Across 41 payments — averaging $223.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vantive US Healthcare LLC$5K
  • Baxter Healthcare$1K
  • Mallinckrodt Hospital Products Inc.$545
  • Akebia Therapeutics Inc$375
  • AstraZeneca$250
  • Ardelyx, Inc.$250
  • plus $1K from 11 others

What the payments were for

  • Travel & lodging$1,61018%
  • Food & beverage$3,35637%
  • Education$4,21446%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,179 in reported general payments places this provider in the 75th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$105,399
Medicare patients
275
Services billed
817

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide12$34,928
FarxigaDapagliflozin Propanediol24$26,577
KerendiaFinerenone12$11,198
Sevelamer Carbonate13$3,462
Methenamine Hippurate18$2,299
Gentamicin Sulfate29$1,462
Nifedipine ErNifedipine30$1,341
Bumetanide29$796
Calcitriol67$783
Tacrolimus11$770
Allopurinol44$591
Losartan Potassium60$525
Amlodipine Besylate75$491
Furosemide46$405
Carvedilol42$396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$141$34,92812 claims
AstraZenecaFarxiga$250$26,57724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,341 nephrology providers in California.

Other nephrology in Colton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →